Grunenthal Logo

External Link

You are now leaving the Grünenthal (UK) website. You will be re-directed to an external website. Grünenthal UK Ltd. accepts no responsibility for the content of other websites.

Grünenthal Campus, Aachen Germany

Where we come from

Although firmly rooted in Germany, today we are very much a growing global business. As an integrated research and development company, we have a strong track record of bringing pain treatments to patients.

Grünenthal Ltd., UK, a subsidiary of Grünenthal GmbH, was established in 2004. With headquarters in TOR Building, Saint-Cloud Way, Maidenhead SL6 8BN, the company includes Regulatory, Medical Information, Sales and Marketing divisions as well as Market Access and Medical Science Liaison teams.

Two business men talking

2022 Nebido® (Testosterone undecanoate)

2017 Acquisition of Qutenza™ (capsaicin 179mg cutaneous patch)

Qutenza
Recivit®

2014 Recivit® (fentanyl) & Palexia® (tapentadol oral solution) Launch

Please note Recivit® is no longer marketed by Grunenthal UK.

2011 Launch of Palexia® (tapentadol tablets) and Palexia SR® (tapentadol prolonged release)

Happy couple
Versatis® is launched in the EU

2007 Launch of Versatis® (lidocaine 700mg medicated plaster)

2006 Company launched to promote Zydol® and Zydol® SR (tramadol hydrochloride)

Grünenthal Ltd, UK, Stokenchurch

2004 Foundation

Grünenthal UK made their first sales.

M-N/A-UK-07-25-0006 December 2025